Sarepta Therapeutics Inc (SRPT)

$ 20.22
   
  • Change Today:
    $0.16
  • 52 Week High: $143.45
  • 52 Week Low: $12.88
  • Currency: US Dollars
  • Shares Issued: 66.44m
  • Volume: 9,540,270
  • Market Cap: $1,343.47m
  • RiskGrade: 650

Latest ShareCast News

FDA grants fast-track designation for Sarepta's muscular dystrophy treatment

By Alexander Bueso

Date: Friday 24 Jul 2020

(Sharecast News) -

Sarepta Therapeutics flies after partnering with Roche on DMD gene therapy

By Alexander Bueso

Date: Monday 23 Dec 2019

(Sharecast News) - Switzerland's Roche has bought the rights to launch and sell one of Sarepta Therapeutics's gene therapy treatments for Duchenne muscular dystrophy outside of the States, sending shares in the US-based biotechnology outfit flying in premarket trading.

RBC stays at 'buy' on Sarepta Therapeutics, believes in 'ultimate success'

By Alexander Bueso

Date: Thursday 10 Oct 2019

(Sharecast News) - Analysts at RBC reiterated their recommendation to 'buy' shares of Sarepta, expressing confidence in the efficacy of the gene therapy specialist's muscular distrophy programmes, telling clients that they believed they would "ultimately succeed".

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

SRPT Market Data

Currency US Dollars
Share Price $ 20.22
Change Today $ 0.16
% Change 0.80 %
52 Week High $143.45
52 Week Low $12.88
Volume 9,540,270
Shares Issued 66.44m
Market Cap $1,343.47m
RiskGrade 650

What The Brokers Say

Strong Buy 6
Buy 2
Neutral 16
Sell 4
Strong Sell 2
Total 30
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Trades for 22-Aug-2025

Time Volume / Share Price
15:59 391 @ $20.22
15:59 100 @ $20.21
15:59 199 @ $20.21
15:59 100 @ $20.21
15:59 100 @ $20.21

Top of Page